This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LHC Group (LHCG) Forays Into Oregon With New Acquisition
by Zacks Equity Research
LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.
PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.
Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
by Zacks Equity Research
Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.
Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?
by Zacks Equity Research
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex (LMNX) Files EUA Application for New Respiratory Assay
by Zacks Equity Research
Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.
Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Luminex (LMNX) Q4 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Is Luminex (LMNX) Down 0.8% Since Last Earnings Report?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
Luminex (LMNX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Luminex (LMNX) Down 34.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2
Luminex (LMNX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.
Luminex (LMNX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Luminex (LMNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.
Luminex (LMNX) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Luminex (LMNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.